Table 2:

Treatment Characteristics

Variable	n (%)
Upfront Therapy  COPP-ABV  ABVE-PC  MSK-MDP  ABVD  MOPP-based  AV-PC  BEACOPP  Other*	9 (25%) 7 (19.4%) 5 (13.9%) 5 (13.9%) 4 (11.1%) 2 (5.6%) 2 (5.6%) 2 (5.6%)
Salvage Therapy  ICE  Vinorelbine and/or gemcitabine-containing regimen  Ifofamide/Etoposide  Brentuximab-vedotin-containing regimen  Variable other regimens**  Data unavailable	12 (33.3%) 12 (33.3%) 4 (11.1%) 4 (11.1%) 3 (8.3%) 1 (2.8%)
Radiation therapy:  At initial diagnosis  At relapse (salvage therapy or ASCT preparative regimen)  After ASCT	20 (55.6%) 29 (80.6%) 2 (5.6%)
Preparative Regimen  Cyclophosphamide Etoposide TLI  Cyclophosphamide Etoposide Carmustine  BEAM	14 (38.9%) 18 (50%) 4 (11.1%)
Disease Status at ASCT  CR  PR  SD  PD	22 (61.1%) 5 (13.9%) 6 (16.7%) 3 (8.3%)
BMT Date  ≤1997  >1997	18 (50%) 18 (50%)

COPP-ABV, Cyclophosphamide, Vincristine, Prednisone, Procarbazine, Doxorubicin, Bleomycin, Vinblastine; ABVE-PC, Doxorubicin, Bleomycin, Vincristine, Etoposide, Prednisone, Cyclophosphamide; MSK-MDP, Doxorubicin, Procarbazine, Prednisone, Vincristine, Cyclophosphamide; ABVD, Doxorubicin, Bleomycin, Vinblastine, Dacarbazine; MOPP, Mustargen, Vincristine, Procarbazine, Prenisone; AV-PC, Doxorubicin, Vincristine, Prednisone, Cyclophosphamide; BEACOPP, Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone; ICE, Ifosfamide, Carboplatin, Etoposide; Cy, Cyclophosphamide; Etop, Etoposide; BEAM, Carmustine, Etoposide, Cytarabine, Melphalan.

^*Other up front chemotherapy regimens include: VAMP (Vincristine, Doxorubicin, Methotrexate, Prednisone) and OPPA (Vincristine, Prednisone, Procarbazine, Doxorubicin).

^**Variable other regimens include: Doxorubicin, etoposide, cyclophosphamide (n=1), DECAL (n=1), BEACOPP (n=1)